MUOVITI.life : Empowering the Autonomous Patient

Extending clinical intelligence into patient sovereignty — from an implant card received at discharge to a lifelong, portable record of care, recovery and outcomes.

MAIVAN.ai Surgical Intelligence | 28 October 2026

Patient-centered is not yet patient-sovereign

Healthcare organizations increasingly promise patient-centered care. Patients are invited to participate in treatment decisions, receive access to portals and complete questionnaires about their recovery. These are valuable advances. Yet patient-centered care does not necessarily give individuals effective control over their longitudinal health information, their digital representation or the secondary uses of their data.

Medical records remain dispersed among hospitals, specialists, rehabilitation providers and insurers. Implant details may exist in the hospital’s operating-room documentation, while information about pain, mobility and the return to everyday life is recorded somewhere else—or not at all.

MAIVAN.ai’s MUOVITI.life initiative explores a different proposition:

Patient-centered healthcare is a promise made by institutions. Patient-sovereign healthcare is a capability held by individuals.

The ambition is not to transfer every legal or clinical responsibility from healthcare institutions to individuals. It is to equip people with practical rights and tools: the ability to access an understandable record, carry it between providers, contribute their own observations, decide when optional sharing is appropriate and see how authorized uses are governed.

Start with something concrete: the patient who receives an implant

Imagine a 67-year-old woman undergoing total hip replacement. The hospital knows her diagnosis, the operation performed, the implanted components, the relevant device identifiers and the initial rehabilitation plan. At discharge, she receives instructions and documentation. Months later she may see a physiotherapist, a general practitioner or another orthopaedic specialist. Years later, she may move, travel or need an implant assessment at a different hospital.

Why should she have to reconstruct the history of her implant and recovery from multiple institutions?

The proposed MUOVITI Pass is a portable digital patient passport connecting diagnosis, treatment, implant identity, rehabilitation and longitudinal outcomes. The starting point is deliberately simple: give the patient access to a legible, portable account of what happened and what device was implanted, then allow that record to grow with the patient’s journey.

The Pass might initially contain a discharge summary, the implantation date, the affected side, implant manufacturer and model, applicable unique device identification (UDI), relevant clinical instructions and contacts for follow-up. Over time, it could incorporate treatment milestones, physiotherapy information, patient-reported outcomes and new clinical encounters.

This is not a replacement for the hospital’s official medical record. Nor does the Pass change hospitals’ legal recordkeeping obligations. It is a patient-controlled access, portability and participation layer built around authorized clinical information.

Why implant identity provides a practical launch point

Implant documentation is already part of medical-device safety. In Switzerland, Article 20 of the Medical Devices Ordinance (MedDO/MepV) governs information and implant cards for covered implantable medical devices, drawing on Article 18 of the EU Medical Device Regulation. The rules include exemptions: for example, certain screws, plates and pins are excluded from the implant-card obligation. The statutory requirement must therefore be assessed by device type, not assumed to apply to every implant.

For covered devices, the existing information flow creates an opportunity for a patient-facing digital extension. A hospital could offer a QR code at discharge to initiate MUOVITI Pass onboarding. The patient would then verify their identity and import or receive the permitted implant and treatment information through a secure process. A QR code should never itself expose sensitive clinical data or act as an unrestricted access token.

The Pass would add value beyond a static implant card by connecting the device identity to the wider care journey: why treatment was performed, how rehabilitation is progressing, what outcomes matter to the patient and whether further clinical follow-up is necessary.

From the hospital’s case to the patient’s journey

MAIVAN.ai’s ORTHO-X initiative proposes a clinical intelligence and evidence layer for orthopaedics. Its OrthoFlow workflows and Case Capsule architecture aim to connect diagnosis, imaging, treatment decisions, operative documentation, implant details, rehabilitation and outcomes while preserving appropriate institutional data controls.

MUOVITI.life offers a complementary perspective. ORTHO-X supports the clinical workflow and its evidence. The MUOVITI Pass enables the patient to access and contribute to a portable longitudinal representation of that evidence.

Consider the same hip replacement across five stages:

  1. Before treatment: The patient records symptoms, functional limitations, prior treatments and personal goals. Clinicians maintain responsibility for reviewing and interpreting this information.
  2. At discharge: Authorized diagnostic, procedural and implant information is added to the Pass, with links or references to the authoritative hospital records.
  3. During rehabilitation: The patient—or an authorized representative—can add pain, mobility, activity and recovery observations, using accessible questionnaires rather than burdensome data entry.
  4. At follow-up: The treating team can review appropriately shared outcome trends alongside clinical assessments and imaging. Automated flags, if introduced, require defined clinical rules and validation.
  5. Years later: When seeking a second opinion or changing providers, the patient can present an exportable record of implant identity and care history without being permanently locked into one application or cloud provider.

The objective is continuity of meaning, not merely continuity of storage.

Outcomes should describe the life the patient regains

An operation can be technically successful while the patient continues to experience pain, limited mobility or difficulty returning to work and daily activities. Conversely, a patient’s recovery may reveal benefits invisible in conventional procedural metrics.

MUOVITI.life aims to make these experiences part of the longitudinal evidence rather than an afterthought. Internationally developed outcome sets offer a useful starting point. For example, ICHOM’s Hip & Knee Osteoarthritis Standard Set recommends patient-centered measures addressing pain, physical function and quality of life.

For a person with a new hip implant, the Pass might display changes in walking ability, pain and daily activities against the individual’s own baseline. The design should represent uncertainty and missing responses clearly; it must not turn simple self-reports into unsupported medical diagnoses.

Over time, suitable and voluntarily connected activity devices may enrich the picture, but a smartphone or wearable must not become a prerequisite for meaningful participation. Older patients, people with disabilities and those requiring caregiver support should be included by design.

A patient-sovereign architecture: access, choice and accountability

The phrase patient sovereignty must mean something operational. MUOVITI.life’s proposed Patient Sovereignty Charter centers on five principles:

  1. Identity and representation: The individual can authenticate securely, understand what the Pass contains and appoint an authorized representative where appropriate.
  2. Portability and exit: The patient can obtain a complete, usable export of their portable record and move to another qualified custodian without being permanently dependent on MUOVITI.life.
  3. Purpose-specific authorization: Optional access and secondary uses are requested transparently, with meaningful controls and revocation where legally and technically applicable.
  4. Provenance and auditability: The Pass distinguishes hospital-originated records, patient contributions and AI-generated summaries; relevant access and sharing events are auditable.
  5. Fair participation: If patients voluntarily contribute to permissible research or evidence programmes, any proposed compensation and benefit-sharing rules should be understandable, equitable and separated from clinical care decisions.

These principles do not imply that patients can delete a hospital’s legally retained records, veto every lawful regulatory use or revoke data processing retroactively in all circumstances. They establish the design commitments for a trustworthy patient-controlled service within applicable law.

AI as an assistant—not as the owner of the patient

Clinical intelligence can help people understand their own journey. A carefully constrained AI assistant could explain terminology in a discharge report, organize a timeline of appointments, translate medical information into accessible language or help prepare questions for an upcoming consultation.

It should always distinguish original records from AI-generated interpretations, link explanations to sources where possible and refrain from presenting itself as a substitute for professional clinical advice. Clinical warnings, triage and diagnostic recommendations require separate safety assessment and, where applicable, regulatory authorization.

The underlying model should remain replaceable. MUOVITI.life’s value lies in patient identity, continuity, permissions, interoperable evidence and trusted service design—not dependency on a particular foundation model.

Why hospitals, manufacturers and payers may benefit

A patient-sovereign passport need not be adversarial toward healthcare institutions. Its potential value is to improve cooperation while preserving distinct responsibilities.

Hospitals: continuity and measurable recovery

With patient authorization and suitable integration, hospitals could simplify implant information delivery, maintain post-discharge contact and improve completeness of patient-reported outcome collection. Evidence of clinical benefit and operational savings would need to be established during pilots.

Manufacturers: better longitudinal evidence

Implant manufacturers must conduct appropriate post-market surveillance and, where relevant, post-market clinical follow-up (PMCF). A properly governed longitudinal evidence network could help link implant identity, procedure, patient characteristics and outcomes—including unfavorable results. Manufacturer sponsorship must never determine clinical conclusions or obscure conflicts of interest.

Insurers and purchasers: value-based healthcare

Aggregated, appropriately authorized and risk-adjusted outcomes could eventually inform value-based contracting and quality-oriented procurement. Such analyses must avoid punishing providers who treat higher-risk patients or converting the Pass into an instrument of discriminatory underwriting.

Research and professional societies: outcomes that matter

International outcome frameworks, clinical registries and independently governed research networks could use standardized evidence to study recovery and long-term implant performance, subject to appropriate consent or other lawful basis, security and scientific oversight.

Independent governance, federated evidence and infrastructure freedom

MUOVITI.life should not depend on a single hospital software vendor, implant company, hyperscaler or digital identity provider. The proposed architecture separates the patient’s portable record and authorization experience from the infrastructure used to store or process data.

Hospitals retain their authoritative medical records. Selected data can be represented through interoperable standards and traceable references. Approved analyses may operate locally or through federated arrangements, sharing only outputs permitted by the relevant legal and governance framework. Any claims of anonymization must be evaluated carefully: simply removing names does not guarantee that sensitive medical data cannot be reidentified.

MAIVAN.ai envisages clinical evidence generation through ORTHO-X, while the proposed ERMOS Foundation and DAPSI initiative could contribute independent scientific governance and stakeholder coordination. These are proposed roles, not claims of existing institutional endorsement.

European policy is also moving toward stronger health-data access and interoperability through the European Health Data Space, although its requirements are phased in and the EU framework does not automatically govern Swiss healthcare in the same way.

A focused Swiss demonstrator: 100 patients, one measurable proposition

Rather than beginning with a universal health wallet, MUOVITI.life could test a narrowly scoped deployment with one or two orthopaedic hospitals and approximately 100 consenting patients receiving eligible implants.

The hospital would recommend the Pass at discharge through an understandable onboarding process. The initial record would include verified device identification, selected discharge information and a patient-friendly timeline. Participants would then be invited to contribute agreed outcome measures during recovery.

The demonstrator should test not only patient engagement but also the sovereignty claim itself: Can a patient export the complete portable record, transfer it to another qualified custodian and revoke future optional sharing without depending permanently on MUOVITI.life or the original infrastructure vendor?

Other proposed measures include onboarding completion, follow-up response rates, data completeness, patient comprehension, support burden, interoperability, security incidents and the cost of sustaining the service. Any evaluation of improved care or reduced expenditure would need appropriate study design and comparison data.

Manufacturers and infrastructure providers might contribute funding or technical support through transparent agreements. The patient’s care, access rights and independent research conclusions must not depend on participation in commercial data programmes.

Beyond orthopaedics: the autonomous patient as a new organizing principle

An implant passport is a natural starting point because device identity creates a concrete connection between treatment, safety and long-term follow-up. But the wider idea extends to cardiovascular implants, neuromodulation, rehabilitation, chronic conditions and ultimately a more continuous account of health and care.

The ambition is not for the patient to become a data broker or a full-time administrator of their medical history. It is for digital infrastructure to handle the complexity so the patient gains agency without additional burden.

MUOVITI.life aims to make the patient—not the hospital portal, device manufacturer or cloud platform—the enduring point of continuity across the care journey.

An invitation to build patient sovereignty in practice

MAIVAN.ai welcomes discussions with hospitals, patient organizations, outcomes researchers, implant manufacturers and trusted infrastructure partners interested in a transparent, independently assessable demonstrator.

The first milestone is intentionally modest: a reliable implant-linked patient passport, meaningful follow-up outcomes and demonstrable portability.

The longer-term ambition is more consequential: a healthcare ecosystem in which people can understand their care, participate in generating evidence about outcomes and exercise genuine choice over how their portable health information is used.

Better healthcare should not merely put the patient at the center of the institution’s system. It should give the patient the practical ability to carry their own journey beyond it.

References and further reading

Disclosure: MUOVITI.life and the MUOVITI Pass are proposed initiatives and product concepts. This article presents intended capabilities, potential partnerships and proposed pilot arrangements; it does not claim that they are deployed, clinically validated, contractually agreed or endorsed by named institutions. Medical, privacy and device-regulatory requirements depend on intended use and jurisdiction.


Comments

Leave a Reply

Your email address will not be published. Required fields are marked *